The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Intermittent Porphyria Drugs Market Research Report 2024
Synopsis
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
The global Acute Intermittent Porphyria Drugs market was valued at US$ 49 million in 2023 and is anticipated to reach US$ 56 million by 2030, witnessing a CAGR of 1.8% during the forecast period 2024-2030.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
This report aims to provide a comprehensive presentation of the global market for Acute Intermittent Porphyria Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Intermittent Porphyria Drugs.
Report Scope
The Acute Intermittent Porphyria Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Intermittent Porphyria Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Intermittent Porphyria Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recordati Rare Diseases
Segment by Type
350mg
313mg
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Acute Intermittent Porphyria Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Acute Intermittent Porphyria Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
The global Acute Intermittent Porphyria Drugs market was valued at US$ 49 million in 2023 and is anticipated to reach US$ 56 million by 2030, witnessing a CAGR of 1.8% during the forecast period 2024-2030.
Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
This report aims to provide a comprehensive presentation of the global market for Acute Intermittent Porphyria Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Intermittent Porphyria Drugs.
Report Scope
The Acute Intermittent Porphyria Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Intermittent Porphyria Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Intermittent Porphyria Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Recordati Rare Diseases
Segment by Type
350mg
313mg
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Acute Intermittent Porphyria Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Acute Intermittent Porphyria Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Acute Intermittent Porphyria Drugs Market Overview
1.1 Product Overview and Scope of Acute Intermittent Porphyria Drugs
1.2 Acute Intermittent Porphyria Drugs Segment by Type
1.2.1 Global Acute Intermittent Porphyria Drugs Market Value Comparison by Type (2024-2030)
1.2.2 350mg
1.2.3 313mg
1.3 Acute Intermittent Porphyria Drugs Segment by Application
1.3.1 Global Acute Intermittent Porphyria Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Acute Intermittent Porphyria Drugs Market Size Estimates and Forecasts
1.4.1 Global Acute Intermittent Porphyria Drugs Revenue 2019-2030
1.4.2 Global Acute Intermittent Porphyria Drugs Sales 2019-2030
1.4.3 Global Acute Intermittent Porphyria Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Acute Intermittent Porphyria Drugs Market Competition by Manufacturers
2.1 Global Acute Intermittent Porphyria Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Acute Intermittent Porphyria Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Acute Intermittent Porphyria Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Acute Intermittent Porphyria Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Acute Intermittent Porphyria Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Acute Intermittent Porphyria Drugs, Product Type & Application
2.7 Acute Intermittent Porphyria Drugs Market Competitive Situation and Trends
2.7.1 Acute Intermittent Porphyria Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Acute Intermittent Porphyria Drugs Players Market Share by Revenue
2.7.3 Global Acute Intermittent Porphyria Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Acute Intermittent Porphyria Drugs Retrospective Market Scenario by Region
3.1 Global Acute Intermittent Porphyria Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Acute Intermittent Porphyria Drugs Global Acute Intermittent Porphyria Drugs Sales by Region: 2019-2030
3.2.1 Global Acute Intermittent Porphyria Drugs Sales by Region: 2019-2024
3.2.2 Global Acute Intermittent Porphyria Drugs Sales by Region: 2025-2030
3.3 Global Acute Intermittent Porphyria Drugs Global Acute Intermittent Porphyria Drugs Revenue by Region: 2019-2030
3.3.1 Global Acute Intermittent Porphyria Drugs Revenue by Region: 2019-2024
3.3.2 Global Acute Intermittent Porphyria Drugs Revenue by Region: 2025-2030
3.4 North America Acute Intermittent Porphyria Drugs Market Facts & Figures by Country
3.4.1 North America Acute Intermittent Porphyria Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Acute Intermittent Porphyria Drugs Sales by Country (2019-2030)
3.4.3 North America Acute Intermittent Porphyria Drugs Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Acute Intermittent Porphyria Drugs Market Facts & Figures by Country
3.5.1 Europe Acute Intermittent Porphyria Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Acute Intermittent Porphyria Drugs Sales by Country (2019-2030)
3.5.3 Europe Acute Intermittent Porphyria Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Acute Intermittent Porphyria Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Acute Intermittent Porphyria Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Acute Intermittent Porphyria Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Acute Intermittent Porphyria Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Acute Intermittent Porphyria Drugs Market Facts & Figures by Country
3.7.1 Latin America Acute Intermittent Porphyria Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Acute Intermittent Porphyria Drugs Sales by Country (2019-2030)
3.7.3 Latin America Acute Intermittent Porphyria Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Acute Intermittent Porphyria Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Acute Intermittent Porphyria Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Acute Intermittent Porphyria Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Acute Intermittent Porphyria Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Acute Intermittent Porphyria Drugs Sales by Type (2019-2030)
4.1.1 Global Acute Intermittent Porphyria Drugs Sales by Type (2019-2024)
4.1.2 Global Acute Intermittent Porphyria Drugs Sales by Type (2025-2030)
4.1.3 Global Acute Intermittent Porphyria Drugs Sales Market Share by Type (2019-2030)
4.2 Global Acute Intermittent Porphyria Drugs Revenue by Type (2019-2030)
4.2.1 Global Acute Intermittent Porphyria Drugs Revenue by Type (2019-2024)
4.2.2 Global Acute Intermittent Porphyria Drugs Revenue by Type (2025-2030)
4.2.3 Global Acute Intermittent Porphyria Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Acute Intermittent Porphyria Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Acute Intermittent Porphyria Drugs Sales by Application (2019-2030)
5.1.1 Global Acute Intermittent Porphyria Drugs Sales by Application (2019-2024)
5.1.2 Global Acute Intermittent Porphyria Drugs Sales by Application (2025-2030)
5.1.3 Global Acute Intermittent Porphyria Drugs Sales Market Share by Application (2019-2030)
5.2 Global Acute Intermittent Porphyria Drugs Revenue by Application (2019-2030)
5.2.1 Global Acute Intermittent Porphyria Drugs Revenue by Application (2019-2024)
5.2.2 Global Acute Intermittent Porphyria Drugs Revenue by Application (2025-2030)
5.2.3 Global Acute Intermittent Porphyria Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Acute Intermittent Porphyria Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Recordati Rare Diseases
6.1.1 Recordati Rare Diseases Corporation Information
6.1.2 Recordati Rare Diseases Description and Business Overview
6.1.3 Recordati Rare Diseases Acute Intermittent Porphyria Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Recordati Rare Diseases Acute Intermittent Porphyria Drugs Product Portfolio
6.1.5 Recordati Rare Diseases Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Acute Intermittent Porphyria Drugs Industry Chain Analysis
7.2 Acute Intermittent Porphyria Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Acute Intermittent Porphyria Drugs Production Mode & Process
7.4 Acute Intermittent Porphyria Drugs Sales and Marketing
7.4.1 Acute Intermittent Porphyria Drugs Sales Channels
7.4.2 Acute Intermittent Porphyria Drugs Distributors
7.5 Acute Intermittent Porphyria Drugs Customers
8 Acute Intermittent Porphyria Drugs Market Dynamics
8.1 Acute Intermittent Porphyria Drugs Industry Trends
8.2 Acute Intermittent Porphyria Drugs Market Drivers
8.3 Acute Intermittent Porphyria Drugs Market Challenges
8.4 Acute Intermittent Porphyria Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
